FCRL4 and colorectal carcinoma: BTLA, FCRL4 and SIGLEC6, which have been shown to inhibit BCR signaling (26), have been found to be highly expressed in CRC from patients with shorter OS, by Kaplan Meyer curves of the PanCancer cohort, and in CRC of short-term survivors from the validation cohort, as detected by immunopathology.